Scroll for more



Partnership Opportunities

At Sucampo, we challenge ourselves to continue to find new and innovative pharmaceutical solutions to help improve the lives of patients. We believe in our own expertise and proven capabilities, but know that sometimes the best results come from collaborating with other experts in the field through in-licensing or acquiring products, developing strategic alliances or out-licensing our products.


We are actively exploring an expansion of our
collaborations and are open to working with all
types of partners or opportunities. Our goal is to
provide excellent value to our partners in each
relationship we enter.

Before moving forward, we will carefully review
each opportunity presented to us and a member
of our business development team will be in
touch to discuss.


Below are examples of the types of partnerships we’re interested in:


Product Acquisitions / In-Licensing

Strategic Alliances



For Business Development inquiries please contact:

Woody Bryan, Ph.D.

Senior Vice President, Business Development and Licensing


Phone: +1-240-223-3617

Contact Us
Tel: +1-301-961-3400

Sucampo Pharmaceuticals, Inc. is focused on the development and commercialization of specialized medicines that meet major unmet medical needs of patients worldwide. Sucampo has two marketed products – AMITIZA, its lead product, and RESCULA – and a late-stage pipeline of product candidates in clinical development for orphan disease areas. VTS-270 is a mixture of 2-hydroxypropyl-B-cyclodextrins with a specific compositional fingerprint that has been granted orphan designation in the U.S. and Europe and is in a pivotal Phase 2/3 clinical trial for the treatment of Niemann-Pick Disease Type C-1. Sucampo has an option for the North American rights to CPP1- x/sulindac, which is in Phase 3 development for the treatment of familial adenomatous polyposis and has been granted orphan drug designation in the U.S. A global company, Sucampo is headquartered in Rockville, Maryland, and has operations in Japan and Switzerland.